

Form 27

Securities Act

Material Change Report Under Section 118(1) of the Securities Act

CONFIDENTIAL – SECTION 118

I. FULL NAME: Reporting Issuer

Altachem Pharma Ltd.

II. ADDRESS OF PRINCIPAL OFFICE:

17215 108 Avenue NW
Edmonton, Alberta
T5S 1G2

III. DATE OF MATERIAL CHANGE:

March 3, 2000

IV. NEWS RELEASE:

March 6, 2000
BCE Emergis

V. SUMMARY OF MATERIAL CHANGE:

Altachem Pharma Ltd.

Trading Symbol “AAF”: Canadian Venture Exchange (CDNX)

News Release

March 6, 2000

Warren Jackson, President and CEO of Altachem Pharma Ltd. is pleased to announce the signing of an exclusive wholesale distribution agreement with TransHealth International Inc. of Newport Beach, California.

Altachem Pharma has the exclusive right to distribute TransHealth International Inc.’s series of Rapid Test Kits designed for self-diagnosis to screen HIV 1&2, HIV 1,2&0 Hepatitis B, Prostate PSA, Six-In-One Drug Screening and various other pregnancy and ovulation tests. The territory included in the agreement is Asia excluding Korea, Japan, Taiwan and the Philippines.

The accuracy of the Rapid Test Screening devices are among the highest when compared to other commercially available tests, for example:

- Hepatitis B Test: over 99% ACCURATE

- HIV 1&2 Test: greater than 99.5% ACCURATE

The series of kits require either a blood sample or urine sample but do not require nurses or technicians. Each kit is designed as a self-contained unit so expensive analytical equipment or laboratory work is not required. The tests show results in five to ten minutes (depending on the test) and are very low cost which makes them very attractive to the Asian market. The kits are designed as a screening test and upon positive results the individual should consult a doctor or physician for a more thorough test.

For more information, please visit us on the **WEB** at www.altachempharma.com or contact Roger Andrews, Investor Relations at;

Phone: (780) 448-1400
Fax: (780) 448-1436
Toll Free Phone: (877) 502-5939
E-mail : Roger@altachempharma.com

VI. RELIANCE ON SECTION 118(2) OF THE SECURITIES ACT:

N/A

VII. OMITTED INFORMATION:

N/A

VIII. SENIOR OFFICERS:

NAME: Warren Jackson
BUSINESS PHONE: (780)448-1400

CONTACT NAME: Doug Jewell
BUSINESS PHONE: (780)448-1400

IX. STATEMENT OF SENIOR OFFICER:

The foregoing accurately discloses the material change referred to in this report.

March 6, 2000
Altachem Pharma Ltd.

IT IS AN OFFENCE UNDER THE *SECURITIES ACT* AND THE *SECURITIES REGULATION* FOR A PERSON OR COMPANY TO MAKE A STATEMENT IN A DOCUMENT REQUIRED TO BE FILED OR FURNISHED UNDER THE ACT IN THE LIGHT OF THE CIRCUMSTANCES UNDER WHICH IT IS MADE, IS A MISREPRESENTATION.